Key result
Natural antiangiogenic compounds demonstrate potential therapeutic benefits in the treatment and prevention of liver inflammation and steatohepatitis.
Why the study?
Antiangiogenic therapy may benefit alcoholic and non-alcoholic fatty liver diseases, prompting interest in understanding the molecular mechanisms of natural antiangiogenic compounds to prevent and control steatohepatitis.
Do natural antiangiogenic compounds prevent or control liver inflammation in patients with ALD or NAFLD?
Do natural antiangiogenic compounds prevent or control liver inflammation in patients with ALD or NAFLD?
Natural antiangiogenic compounds may offer therapeutic benefits in the treatment of hepatic inflammation and steatohepatitis.
May support inflammation monitoring in ALD/NAFLD; leaves open immunomodulatory targets for ASH/NASH.
Alcoholic Liver Disease (ALD) and Non-Alcoholic Fatty Liver Disease (NAFLD) are the most common causes of chronic liver disease and are increasingly emerging as a global health problem. Such disorders can lead to liver damage, resulting in the release of pro-inflammatory cytokines and the activation of infiltrating immune cells. These are some of the common features of ALD progression in ASH (alcoholic steatohepatitis) and NAFLD to NASH (non-alcoholic steatohepa-titis). Hepatic steatosis and subsequent fibrosis, whose continuous progression is accompanied by angiogenesis, lead to hypoxia, inducing the activation of vascular factors, which in turn triggers pathological angiogenesis and subsequent fibrosis, resulting in a vicious cycle. This condition further exacerbates liver injury and may contribute to the development of comorbidities, such as metabolic syndrome as well as hepatocellular carcinoma. Increasing evidence suggests that antiangiogenic therapy may have beneficial effects on these hepatic disorders and their exacerbation. Therefore, there is a great interest to deepen the knowledge of the molecular mechanisms of natural antiangiogenic products that could both prevent and control liver diseases. In this review, we focus on the role of major natural antian-giogenic compounds against steatohepatitis and determine their potential therapeutic benefits in the treatment of liver inflammation.
No takes yet. Share an insight, caveat, or question.
Novi et al. (2023) conducted a review in Hepatic inflammation, Alcoholic Liver Disease (ALD), and Non-Alcoholic Fatty Liver Disease (NAFLD). Natural antiangiogenic compounds was evaluated. Natural antiangiogenic compounds demonstrate potential therapeutic benefits in the treatment and prevention of liver inflammation and steatohepatitis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: